Condition

Acute hepatitis B

Clinical trials and treatment information for Acute hepatitis B

7.3M

People Affected

Active Trials

New Cases/Year

36K

Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

Tenofovir alafenamide (TAF)

85% Effectiveness• 80% Confidence• 72% Safety• 2 trials• 400 participants

HIGH EvidencePoor ValueDose: 25 mg orally once daily

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

2-4 weeks for initial viral response, clinical improvement varies

Duration

Variable, typically 6-12 months post HBsAg seroconversion or longer in severe cases

Response Rate

80%

Remission Rate

70%

Common Side Effects:

Nausea: 7%

Headache: 5%

Diarrhea: 3%

Abdominal pain: 3%

Renal impairment (less common than TDF): 0.5%

Bone mineral density loss (less common than TDF): 0.5%

Annual Cost of Care

Drug Cost

$18,000

Monitoring

$750

Side Effects

$100

Total Annual

$18,850

Cost-Effectiveness

POOR

QALYs Gained

0.3

Cost per Remission

$26,928

Cost per Responder

$23,562

Treatment Outcomes

Primary Outcomes

HBV DNA Viral Load7.5 log10 IU/mL

-99.999% (-5.0 log10 IU/mL)

Alanine Aminotransferase (ALT)800 IU/L

-96.25% (-770 IU/L)

HBeAg Seroconversion Rate0% of patients

+55% (+55% of patients)

Secondary Benefits

Total Bilirubin15 mg/dL

-94.67% (-14.2 mg/dL)

International Normalized Ratio (INR)2.5

-60% (-1.5)

Estimated Glomerular Filtration Rate (eGFR)95 mL/min/1.73m^2

+1% (+0.95 mL/min/1.73m^2)

Common Side Effects

Nausea

+7%

Headache

+5%

Diarrhea

+3%

Clinical Trial Phases:

Phase 3Phase 4

Entecavir

80% Effectiveness• 75% Confidence• 68% Safety• 4 trials• 500 participants

MODERATE EvidenceGood ValueDose: 0.5 mg orally once daily

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

2-4 weeks for initial viral response, clinical improvement varies

Duration

Variable, typically 6-12 months post HBsAg seroconversion or longer in severe cases

Response Rate

75%

Remission Rate

65%

Common Side Effects:

Headache: 6%

Fatigue: 4%

Dizziness: 3%

Nausea: 3%

Abdominal pain: 3%

Lactic acidosis (rare): 0.1%

Renal impairment (less common than TDF): 1%

Annual Cost of Care

Drug Cost

$600

Monitoring

$750

Side Effects

$100

Total Annual

$1,450

Cost-Effectiveness

GOOD

QALYs Gained

0.3

Cost per Remission

$2,231

Cost per Responder

$1,933

Treatment Outcomes

Primary Outcomes

HBV DNA Level1.0 x 10^8 IU/mL

-99.99% (Reduced to Undetectable (<20 IU/mL))

ALT (Alanine Aminotransferase) Level1800 U/L

-97.22% (-1750 U/L (to normalization))

INR (International Normalized Ratio)2.1

-47.62% (-1.0 (towards normal))

Total Bilirubin Level8.0 mg/dL

-81.25% (-6.5 mg/dL (towards normal))

Secondary Benefits

Overall Survival Rate (in severe/fulminant acute HBV)60% (expected without treatment in severe cases)

+33.33% (+20 percentage points (from 60% to 80%))

Duration of Hospitalization14 days (for severe acute HBV)

-35.71% (-5 days)

SF-36 Physical Component Summary (PCS) Score35 points (lower scores indicate poorer physical health)

+42.86% (+15 points)

Common Side Effects

Headache

+6%

Fatigue

+4%

Dizziness

+3%

Clinical Trial Phases:

Phase 3Phase 4

Tenofovir disoproxil fumarate (TDF)

80% Effectiveness• 75% Confidence• 60% Safety• 3 trials• 500 participants

MODERATE EvidenceGood ValueDose: 300 mg orally once daily

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

2-4 weeks for initial viral response, clinical improvement varies

Duration

Variable, typically 6-12 months post HBsAg seroconversion or longer in severe cases

Response Rate

75%

Remission Rate

65%

Common Side Effects:

Nausea: 8%

Diarrhea: 6%

Headache: 5%

Abdominal pain: 5%

Renal impairment: 3%

Bone mineral density loss: 3%

Lactic acidosis (rare): 0.1%

Annual Cost of Care

Drug Cost

$480

Monitoring

$900

Side Effects

$200

Total Annual

$1,580

Cost-Effectiveness

GOOD

QALYs Gained

0.3

Cost per Remission

$2,431

Cost per Responder

$2,107

Treatment Outcomes

Primary Outcomes

HBV DNA Viral Load1.0 x 10^8 IU/mL

-99.999% (Reduction of approximately 6 log10 IU/mL)

Alanine Aminotransferase (ALT)800 IU/L

-95% (-760 IU/L)

Total Bilirubin5.0 mg/dL

-80% (-4.0 mg/dL)

Secondary Benefits

Prothrombin Time (INR)1.8

-39% (-0.7)

Serum Albumin3.0 g/dL

+33% (+1.0 g/dL)

Gamma-Glutamyl Transferase (GGT)200 IU/L

-75% (-150 IU/L)

Common Side Effects

Nausea

+8%

Diarrhea

+6%

Headache

+5%

Clinical Trial Phases:

Phase 3Phase 4